First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)
NCT07285889
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Acute Graft Versus Host Disease
Interventions
DRUG:
Gecacitinib (also known as Jaktinib) combined glucocorticoids
Sponsor
First Affiliated Hospital of Zhejiang University